UniProt Q03181
Peroxisome proliferator-activated receptor delta (Q03181)
Peroxisome proliferator-activated receptor delta (UniProt Q03181): 90 experimental structures on GenesisL1, 34 ligands bound, 33 pockets. Binding sites, pockets, druggability and 3D structures in GL1X.
- UniProt
- Q03181
- Protein
- Peroxisome proliferator-activated receptor delta
- Experimental structures
- 90
- Predicted models
- 0
- Ligands
- 34
- Pockets
- 33 · 6 records with a druggable one
Structures
90 records of Q03181 in the MolNFT archive: 90 experimental, 0 predicted.
| Entry | Title | Method | Chains | Ligands | Pockets |
|---|---|---|---|---|---|
| 1GWX | Molecular recognition of fatty acids by peroxisome proliferator-activated receptors | x-ray diffraction | A, B | — | — |
| 1GWX | Molecular recognition of fatty acids by peroxisome proliferator-activated receptors | x-ray diffraction | A, B | — | — |
| 1Y0S | Crystal structure of PPAR delta complexed with GW2331 | x-ray diffraction | A, B | — | — |
| 1Y0S | Crystal structure of ppar delta complexed with GW2331 | x-ray diffraction | A, B | — | — |
| 2AWH | Human Nuclear Receptor-Ligand Complex 1 | x-ray diffraction | A, B | — | — |
| 2AWH | Human nuclear receptor-ligand complex 1 | x-ray diffraction | A, B | — | — |
| 2B50 | Human Nuclear Receptor-Ligand Complex 2 | x-ray diffraction | A, B | — | — |
| 2B50 | Human nuclear receptor-ligand complex 2 | x-ray diffraction | A, B | — | — |
| 2BAW | Human Nuclear Receptor-Ligand Complex 1 | x-ray diffraction | A, B | — | — |
| 2BAW | Human nuclear receptor-ligand complex 1 | x-ray diffraction | A, B | — | — |
| 2ENV | Solution structure of the C4-type zinc finger domain from human Peroxisome proliferator-activated… | solution nmr | A | — | — |
| 2ENV | Solution structure of the C4-type zinc finger domain from human peroxisome proliferator-activated… | solution nmr | A | — | — |
| 2GWX | Molecular recognition of fatty acids by peroxisome proliferator-activated receptors | x-ray diffraction | A, B | — | — |
| 2GWX | Molecular recognition of fatty acids by peroxisome proliferator-activated receptors | x-ray diffraction | A, B | — | — |
| 2J14 | 3,4,5-Trisubstituted Isoxazoles as Novel PPARdelta Agonists: Part2 | x-ray diffraction | A, B | — | — |
| 2J14 | 3,4,5-trisubstituted isoxazoles as novel ppardelta agonists: PART2 | x-ray diffraction | A, B | — | — |
| 2Q5G | Ligand binding domain of PPAR delta receptor in complex with a partial agonist | x-ray diffraction | A, B | — | — |
| 2Q5G | Ligand binding domain of ppar delta receptor in complex with a partial agonist | x-ray diffraction | A, B | — | — |
| 2XYJ | Novel Sulfonylthiadiazoles with an Unusual Binding Mode as Partial Dual Peroxisome… | x-ray diffraction | A, B | — | — |
| 2XYJ | Novel sulfonylthiadiazoles with an unusual binding mode as partial dual peroxisome… | x-ray diffraction | A, B | — | — |
| 2XYW | Novel Sulfonylthiadiazoles with an Unusual Binding Mode as Partial Dual Peroxisome… | x-ray diffraction | A, B | — | — |
| 2XYW | Novel sulfonylthiadiazoles with an unusual binding mode as partial dual peroxisome… | x-ray diffraction | A, B | — | — |
| 2XYX | Novel Sulfonylthiadiazoles with an Unusual Binding Mode as Partial Dual Peroxisome… | x-ray diffraction | A, B | — | — |
| 2XYX | Novel sulfonylthiadiazoles with an unusual binding mode as partial dual peroxisome… | x-ray diffraction | A, B | — | — |
| 2ZNP | Human PPAR delta ligand binding domain in complex with a synthetic agonist TIPP204 | x-ray diffraction | A, B | — | — |
| 2ZNP | Human ppar delta ligand binding domain in complex with a synthetic agonist TIPP204 | x-ray diffraction | A, B | — | — |
| 2ZNQ | Human PPAR delta ligand binding domain in complex with a synthetic agonist TIPP401 | x-ray diffraction | A, B | — | — |
| 2ZNQ | Human ppar delta ligand binding domain in complex with a synthetic agonist TIPP401 | x-ray diffraction | A, B | — | — |
| 3D5F | Crystal Structure of PPAR-delta complex | x-ray diffraction | A, B | — | — |
| 3D5F | Crystal structure of ppar-delta complex | x-ray diffraction | A, B | — | — |
| 3DY6 | PPARdelta complexed with an anthranilic acid partial agonist | x-ray diffraction | A, B | — | — |
| 3DY6 | Ppardelta complexed with an anthranilic acid partial agonist | x-ray diffraction | A, B | — | — |
| 3ET2 | Structure of PPARdelta with 3-[5-Methoxy-1-(4-methoxy-benzenesulfonyl)-1H-indol-3-yl]-propionic acid | x-ray diffraction | A, B | — | — |
| 3ET2 | Structure of ppardelta with 3-[5-methoxy-1-(4-methoxy- benzenesulfonyl)-1H-indol-3-yl]-propionic… | x-ray diffraction | A, B | — | — |
| 3GWX | Molecular recognition of fatty acids by peroxisome proliferator-activated receptors | x-ray diffraction | A, B | — | — |
| 3GWX | Molecular recognition of fatty acids by peroxisome proliferator-activated receptors | x-ray diffraction | A, B | — | — |
| 3GZ9 | Crystal Structure of Peroxisome Proliferator-Activated Receptor Delta (PPARd) in Complex with a… | x-ray diffraction | A | — | — |
| 3GZ9 | Crystal structure of peroxisome proliferator-activated receptor delta (ppard) in complex with a… | x-ray diffraction | A | — | — |
| 3OZ0 | PPAR Delta in complex with azppard02 | x-ray diffraction | A | — | — |
| 3OZ0 | Ppar delta in complex with AZPPARD02 | x-ray diffraction | A | — | — |
| 3PEQ | PPARd complexed with a phenoxyacetic acid partial agonist | x-ray diffraction | A, B | — | — |
| 3PEQ | Ppard complexed with a phenoxyacetic acid partial agonist | x-ray diffraction | A, B | — | — |
| 3SP9 | Structural basis for iloprost as a dual PPARalpha/delta agonist | x-ray diffraction | A, B | — | — |
| 3SP9 | Structural basis for iloprost as a dual PPARALPHA/DELTA agonist | x-ray diffraction | A, B | — | — |
| 3TKM | Crystal structure PPAR delta binding GW0742 | x-ray diffraction | A | — | — |
| 3TKM | Crystal structure ppar delta binding GW0742 | x-ray diffraction | A | — | — |
| 5U3Q | Human ppardelta ligand-binding domain in complexed with specific agonist 1 | x-ray diffraction | A, B | 7UJ, B7G, K, CL | — |
| 5U3R | Human PPARdelta ligand-binding domain in complexed with specific agonist 2 | x-ray diffraction | A, B | B7G, 7V1 | — |
| 5U3R | Human ppardelta ligand-binding domain in complexed with specific agonist 2 | x-ray diffraction | A, B | B7G, 7V1 | — |
| 5U3S | Human ppardelta ligand-binding domain in complexed with specific agonist 3 | x-ray diffraction | A, B | 7V4, B7G, K | — |
| 5U3T | Human ppardelta ligand-binding domain in complexed with specific agonist 4 | x-ray diffraction | A, B | 7UY, B7G | — |
| 5U3U | Human ppardelta ligand-binding domain in complexed with specific agonist 5 | x-ray diffraction | A, B | 7TV, B7G | — |
| 5U3V | Human PPARdelta ligand-binding domain in complexed with specific agonist 6 | x-ray diffraction | A, B | B7G, 7TY | — |
| 5U3V | Human ppardelta ligand-binding domain in complexed with specific agonist 6 | x-ray diffraction | A, B | B7G, 7TY | — |
| 5U3W | Human PPARdelta ligand-binding domain in complexed with specific agonist 7 | x-ray diffraction | A, B | B7G, 7U1 | — |
| 5U3W | Human ppardelta ligand-binding domain in complexed with specific agonist 7 | x-ray diffraction | A, B | B7G, 7U1 | — |
| 5U3X | Human PPARdelta ligand-binding domain in complexed with specific agonist 8 | x-ray diffraction | A, B | 7U4, B7G | — |
| 5U3X | Human ppardelta ligand-binding domain in complexed with specific agonist 8 | x-ray diffraction | A, B | 7U4, B7G | — |
| 5U3Y | Human PPARdelta ligand-binding domain in complexed with specific agonist 9 | x-ray diffraction | A, B | B7G, 7U7 | — |
| 5U3Y | Human ppardelta ligand-binding domain in complexed with specific agonist 9 | x-ray diffraction | A, B | B7G, 7U7 | — |
30 records more on the page itself.
Ligands
- B7G · heptyl beta-D-glucopyranoside · in 34 records
- K · Potassium ion · in 4 records
- 7SS · 6-(2-{[cyclopropyl(4'-methoxy[1,1'-biphenyl]-4-carbonyl)amino]methyl}phenoxy)hexanoic acid · in 2 records
- 7SV · 6-(2-{[cyclopropyl(2'-fluoro[1,1'-biphenyl]-4-carbonyl)amino]methyl}phenoxy)hexanoic acid · in 2 records
- 7SY · 6-(2-{[cyclopropyl(3'-fluoro[1,1'-biphenyl]-4-carbonyl)amino]methyl}phenoxy)hexanoic acid · in 2 records
- 7T1 · {2-methyl-4-[({4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl}methyl)sulfanyl]phenoxy}acetic acid · in 2 records
- 7TY · 6-[2-({cyclopentyl[4-(furan-3-yl)benzene-1-carbonyl]amino}methyl)phenoxy]hexanoic acid · in 2 records
- 7U1 · 6-(2-{[([1,1'-biphenyl]-4-carbonyl)(cyclopropyl)amino]methyl}phenoxy)hexanoic acid · in 2 records
- 7U4 · 6-[2-({cyclopropyl[4-(pyridin-3-yl)benzene-1-carbonyl]amino}methyl)phenoxy]hexanoic acid · in 2 records
- 7U7 · 6-[2-({cyclopropyl[4-(furan-2-yl)benzene-1-carbonyl]amino}methyl)phenoxy]hexanoic acid · in 2 records
- 7UA · 6-[2-({cyclopropyl[4-(furan-3-yl)benzene-1-carbonyl]amino}methyl)phenoxy]hexanoic acid · in 2 records
- 7V1 · 6-[2-({[4-(furan-2-yl)benzene-1-carbonyl](propan-2-yl)amino}methyl)phenoxy]hexanoic acid · in 2 records
- 9RF · {2-methyl-4-[({5-[4-(trifluoromethyl)phenyl]-1,3,4-thiadiazol-2-yl}methyl)sulfanyl]phenoxy}acetic acid · in 2 records
- CL · Chloride ion · in 2 records
- K55 · (2S)-2-{4-butoxy-3-[({[2-fluoro-4-(trifluoromethyl) phenyl]carbonyl}amino)methyl]benzyl}butanoic acid · in 2 records
- PEM · 2-[P-[2-P-chlorobenzamido)ethyl]phenoxy]-2-methylpropionic acid · in 2 records
- 1KF · (3R)-3-methyl-6-[2-[[5-methyl-2-[4-(trifluoromethyl) phenyl]imidazol-1-yl]methyl]phenoxy]hexanoic acid · in 1 record
- 7SM · 6-(2-{[cyclopropyl(3'-methoxy[1,1'-biphenyl]-4-carbonyl)amino]methyl}phenoxy)hexanoic acid · in 1 record
- 7TV · 6-[2-({cyclopentyl[4-(furan-2-yl)benzene-1-carbonyl]amino}methyl)phenoxy]hexanoic acid · in 1 record
- 7UD · 6-[2-({benzyl[4-(furan-3-yl)benzene-1-carbonyl]amino}methyl)phenoxy]hexanoic acid · in 1 record
- 7UG · 6-[2-({benzyl[4-(thiophen-3-yl)benzene-1-carbonyl]amino}methyl)phenoxy]hexanoic acid · in 1 record
- 7UJ · 6-(2-{[([1,1'-biphenyl]-4-carbonyl)(propan-2-yl) amino]methyl}phenoxy)hexanoic acid · in 1 record
- 7UY · 6-[2-({(propan-2-yl)[4-(thiophen-3-yl)benzene-1-carbonyl]amino}methyl)phenoxy]hexanoic acid · in 1 record
- 7V4 · 6-[2-({[4-(furan-3-yl)benzene-1-carbonyl](propan-2-yl) amino}methyl)phenoxy]hexanoic acid · in 1 record
- 81O · 5-[4-butoxy-3-[[[2-fluoranyl-4-(trifluoromethyl) phenyl]carbonylamino]methyl]phenyl]-4,6-dimethyl-pyridine-3-carboxylic acid · in 1 record
- 820 · (2S)-2-[[4-propoxy-3-[[[4-(trifluoromethyl) phenyl]carbonylamino]methyl]phenyl]methyl]butanoic acid · in 1 record
- 82K · (2S)-2-[[4-hexoxy-3-[[[4-(trifluoromethyl) phenyl]carbonylamino]methyl]phenyl]methyl]butanoic acid · in 1 record
- 85B · 2-[2,6-dimethyl-4-[[5-oxidanylidene-4-[4-(trifluoromethyloxy)phenyl]-1,2,4-triazol-1-yl]methyl]phenoxy]-2-methyl-propanoic acid · in 1 record
- 89L · (E)-6-[2-[[[4-(furan-2-yl)phenyl]carbonyl-methyl-amino]methyl]phenoxy]-4-methyl-hex-4-enoic acid · in 1 record
- 8RR · 2-[2-methyl-4-[[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-selenazol-5-yl]methylsulfanyl]phenoxy]ethanoic acid · in 1 record
Elsewhere
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.